PreComb is building a clinical drug efficacy testing platform based on its 3DTwin® technology for ex vivo drug testing on primary patient tumors. Our clinical partners are equipped with PreComb’s 3DTwin® technology for automated and standardized drug testing directly on site. This allows pharma/biotech to test new drugs/combinations on cohorts of tumor twins derived from native tumor tissue in a physiological and cost-efficient manner. We provide clinical evidence for new cancer therapies to increase developmental success rates.